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PEMBANGUNAN DAN PENILAIAN FORMULASI ETOSOMAL TOPIKAL 




Melanoma adalah salah satu jenis kanser kulit yang paling agresif dengan kadar 
kematian yang tinggi jika tidak dirawat. Sebatian berasaskan herba boleh digunakan 
sebagai alternatif dalam terapi kanser seperti melanoma kerana sifat anti-oksidan dan 
anti-radang yang tinggi. Ciri-ciri ini boleh menghentikan angiogenesis, iaitu suatu 
proses pembentukan saluran darah baru yang penting untuk pertumbuhan tumor dan 
metastasis. Walau bagaimana pun bioketersediaan yang lemah kerana polaritas tinggi 
fitokimia mengehadkan keberkesanannya. Orthosiphon stamineus (O.S) adalah herba 
ubatan yang terkenal di Asia Tenggara dan ekstrak pelarut unik herba ini telah 
menunjukkan aktiviti antiangiogenik dan juga terbitan ini kini dalam percubaan 
klinikal untuk kanser payu dara dan kolon. Dalam kajian ini, ekstrak O.S yang 
diseragamkan kepada 6% asid rosmarinic diformulasikan ke dalam bentuk formulasi 
liposomal yang dikenali sebagai etasom. Kedua-dua ekstrak dan perumusan itu dinilai 
untuk keberkesanannya terhadap melanoma in vitro dan in vivo serta sifat-sifat 
farmakokinetik, toksikologi dan fiziko-kimia dinilai. Kaedah rehidrasi filem nipis 
digunakan untuk mempersiapkan formulasi gel liposomal fleksibel yang terdiri 
daripada ekstrak terpiawai daun O.S Kajian Kromatografi Cecair Prestasi Tinggi 
(HPLC) mendedahkan kecekapan pemerangakapan sebanyak 80% untuk asid 
rosmarinic (RA) dalam vesikel etosom. Saiz zarah purata vesikel teroptimum ialah 
138.6 nm. Ekstrak O.S termuat gel etosomal pada kepekatan 1% menunjukkan aliran 
elasto-plastik yang betul dengan tekanan hasil tertentu serta kekerapan bebas G 'dan G 
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", yang boleh memudahkan ekstrak O.S.mencapai penelapan (permeasi) kulit yang 
berkesan dan maksimum. Saiz zarah purata vesikel teroptimum ialah 138.6 nm. 
Ekstrak O.S termuat gel etosomal pada kepekatan 1% menunjukkan aliran elasto-
plastik yang betul dengan tekanan hasil tertentu serta kekerapan bebas G 'dan G ", yang 
boleh memudahkan ekstrak O.S mencapai penelapan (permeasi) kulit yang berkesan 
dan maksimum. Hayat/Tempoh simpan formulasi akhir gel adalah 2.5 bulan pada suhu 
4ºC. Ekstrak O.S termuat vesikel ethosomal menunjukkan hampir 98% penembusan 
transdermal bertambah baik jika dibandingkan dengan gel hidro-ethanolic 
konvensional O.S ekstrak. Hasil kajian penelapan (permeasi) yang dipertingkatkan dan 
penyaringan FTIR kulit menunjukkan bahawa etanol membubarkan lapisan lipid 
membran kulit dan membuka jurang kecil dan penelapan drug/ubat dipertingkatkan. 
Hasil ini mendedahkan bahawa ekstrak O.S termuat vesikel ethosomal boleh dianggap 
sebagai ejen terapeutik kulit yang berkesan bagi rawatan penyakit kulit. Hasil kajian 
ketoksikan dermal akut dan berulang in vivo menunjukkan bahawa kompleks etosom 
O.S mempunyai profil keselamatan yang baik sebagai formulasi aplikasi topikal tanpa 
kesan toksik muncul dalam analisis histologi organ-organ penting. Kajian 
farmakokinetik dan pemendapatan kulit memperlihatkan peningkatan bioketersediaan 
sebatian aktif berbanding ekstrak mentah O.S Akhirnya, kajian model in vivo 
melanoma yang dijalankan ke atas tikus albino Swiss menyokong keputusan in vitro 
anti-kanser. Hasilnya memperlihatkan kesan antikanser formulasi etosomal-O.S 
topikal yang dipertingkat untuk mengendalikan tumor melanoma yang malignan dan 
mencegah metastasis. Keseluruhan penemuan penyelidikan terkini menunjukkan 
bahawa kadar penembusan yang dipertingkat formulasi gel O.S-ethosomal disebabkan 
oleh fleksibiliti dan kestabilan dalam vesikel menyebabkan kesan anti melanoma 
ekstrak secara in vitro dan in vivo yang lebih baik.  
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DEVELOPMENT AND EVALUATION OF TOPICAL ETHOSOMAL 




Melanoma is one of the most aggressive types of skin cancer with high rate of 
fatality if left untreated. Herbal-based compounds can be useful as alternative in cancer 
therapy such as melanoma due to their high anti-oxidant and anti-inflammatory 
properties. These characteristic features can halt angiogenesis, a process of new blood 
vessels formation which is crucial for tumor growth and metastasis. However, poor 
bioavailability due to the high polarity of the phythochemicals limits their 
effectiveness. Orthosiphon stamineus (O.S) is a popular medicinal herb found in South 
East Asia and a unique solvent extract of this herb has been shown to have 
antiangiogenic activity. In this study, the extract of O.S standardized to 6% rosmarinic 
acid was formulated into a liposomal type of formulation known as ethosome. Both 
the extract and the formulation were evaluated for their effectiveness towards 
melanoma in vitro and in vivo and pharmacokinetics, toxicology and physico-chemical 
properties were evaluated. Thin-film rehydration method was employed to prepare the 
flexible liposomal gel formulation composed of standardized extract of O.S leaves. 
High Performance Liquid Chromatography (HPLC) studies revealed 80% entrapment 
efficiency for the rosmarinic acid (RA) in the ethosomal vesicle of the extract as 
marker compound. The average particle size of optimized vesicle was 138.6 nm. O.S 
extract-loaded ethosomal gel at concentration of 1% demonstrated proper elasto-
plastic flow with specific yield stress as well as frequency independent Gʹ and G″, 
which could facilitate achieving effective and maximum skin permeation of O.S 
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extract. Shelf life of final gel formulation was 2.5 months at 4ºC. O.S extract loaded-
ethosomal vesicles showed almost 98% improved transdermal penetration when 
compared to that of the conventional hydro-ethanolic gel of O.S extract. The enhanced 
permeation study results and FTIR screening of the skins suggests that the ethanol 
dissolved the lipid layers of skin membranes and opened up small gaps and enhanced 
drug permeation. These results revealed that O.S extract loaded-ethosomal vesicles 
can be considered as an effective dermal therapeutic agent for the treatment of skin 
ailments. In vitro anticancer and anti-angiogenic studies in melanoma (B16F10) and 
endothelial (EA.hy926) cell lines respectively, demonstrated significant improvement 
in ethosomal vesicle efficacy compared to O.S crude extract alone. In vivo acute and 
repeated dose dermal toxicity studies results showed that ethosomal complex of O.S 
has a good safety profile as a topical formulation with no toxic effect appeared in 
histological analysis of vital organs. Pharmacokinetic and in vivo skin deposition 
studies demonstrated enhanced bioavailability of active compounds compared to crude 
O.S extract. Finally, in vivo melanoma model study that was conducted in Swiss albino 
mice supported the in vitro anticancer results. The results exhibited enhanced 
anticancer effect of topical ethosomal-O.S formulation to control malignant melanoma 
tumor and prevent metastasis. Altogether the discoveries of present research shows 
that the enhanced penetration rate of O.S-ethosomal gel formulation due to its 
flexibility and stability in vesicle caused the improved anti-melanoma effect of the 
extract in vitro and in vivo. 
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CHAPTER 1  
INTRODUCTION 
1.1  Cancer 
Cancer disease involves the abnormal growth of cells that have the ability to 
invade other organs. Normal human cells grow through the process of cell division. 
Cancer cells are able to ignore some critical cell signals that naturally inform cells to 
suppress programmed cell death.  The result is abnormal cell proliferation leading to 
tumor growth.  
 
1.2  Skin Cancer  
Skin cancer generally occurs more frequently than other types of cancers. 
Generally it starts  cells located in epidermis layer of skin which can metastasize to 
other organs (Ko et al., 2010).   
Skin cancer usually appears due to some specific mutations in cell DNA which 
can be stimulated by ultraviolet light (UV). It can be better controlled if diagnosed 
early, otherwise it can be developed into full blown tumors (D'Orazio et al., 2013). 
Skin cancer is not an inherited disease but based on some research people with less 
pigmentation are at higher risk of getting skin cancer, so from this point of view genetic 
can play a role (Scherer et al., 2010). Moreover, the risk of skin cancer increases in 
patients suffering from some unfrequented syndromes with genetic origin (Lomas et 
al., 2012).  
Skin tumor are categorized in 3 groups based on the shape and epidemiology 




1.2.1  Basal Cell Carcinoma 
Basal cell carcinoma is the least malignant and most common form of skin 
cancer, accounting for 80% of cases in the United States (Scotto et al., 1983). With 
this type, stratum basal cells proliferate and invade the dermis and hypodermis. The 
cancer lesions usually occur on sun-exposed areas of the face and appear as shiny, 
dome-shaped nodules that eventually develop into ulcer in the center with a pearly 
edge (Feuerstein et al., 2008). Basal cell carcinoma grows fairly slow and rarely 
metastasize without it being noticed (Randle, 1996). This type of skin cancer is fully 
curable by surgical excision in 99% of cases (Smeets et al., 2004). 
 
1.2.2  Squamous Cell Carcinoma 
Squamous cell carcinoma is the second most common form of skin cancer and 
arises from keratinocytes in the stratum spinosum (D'Orazio et al., 2013). The lesion 
usually appears as a scaly red papule, is small, round, and elevated. Most often, they 
arise on the head (ears, scalp, lip), and hands. Squamous cell carcinoma will grow 
rapidly and metastasize if not removed (Stein et al., 2005). The chances of a complete 
cure are good if the lesion is caught early and removed surgically (or by radiation 
therapy). 
 
1.2.3  Melanoma 
Melanoma is the most rapidly-increasing type of cancer in the world, doubling 
approximately every 10-20 years in fair-skinned populations (Leiter et al., 2014). Like 
many other types of cancers, occurrence raises with age. Young women are the fastest 
rising melanoma population (Argenziano et al., 2010). Some other names of this 
cancer are malignant melanoma and cutaneous melanoma.  
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Most melanoma cells produce melanin; therefore, melanoma neoplasms are 
generally brownish or black in color. However, some types of melanoma can produce 
melanin but do not do so, so lesions may appear pink, brown, or perhaps white in color.  
Melanoma commonly originates in three specific types of skin cell (Eisinger et 
al., 1985), namely squamous cells, basal cells and melanocytes; although statistically 
there is a greater occurrence in melanocytes (Bonazzi et al., 2012). Melanomas might 
occur anywhere on the skin; but they are most likely to begin on the trunk area (chest 
as well as back) in men, or on the legs in women. Melanoma is unusual among African 
Americans; however, when it happens, survival time is typically shorter than for 
Caucasians (Cormier et al., 2006). Melanoma patients with weak immune systems 
such as those going through organ transplants or HIV patients are at higher risk of 
death (Vajdic et al., 2009). 
Melanoma (tumor of melanocytes) is the most risky type of skin malignancy 
since it is very metastatic and impervious to chemotherapy. Currently, it represents 2-
3% of skin tumor cases, however the rate is expanding quickly (3-8% every year in the 
United States) (Saladi et al., 2005). Melanoma normally appears suddenly and around 
33% of cases originate from existing skin moles (Cummins et al., 2006). It normally 
shows up as a spreading darker spot that spreads rapidly to nearby blood and lymph 
vessels (Egan, 2005).  
The best chance to survive melanoma is early discovery and diagnosis. When 
the lesion become more than 4 mm thick, the possibility of survival is poor (Shields et 
al., 2002). Standard treatment for melanoma incorporates surgical extraction along 





Angiogenesis is the growing of new blood vessels out of the available 
vasculature. This multi-step process happens in life in both normal and abnormal 
physical condition, starting before birth and until old age (Moore et al., 2011). 
Capillary vessels are required in virtually all tissues in order to diffuse nutriments. 
Alterations in metabolic process cause relative modifications in angiogenesis and, 
consequently, relative modifications in the capillaries (Cassell et al., 2002). Oxygen is 
a crucial factor in such regulation. Hemodynamic factors are vital for existence of 
blood vessel networks as well as structural adjustments of vessel wall membranes 
(Pries et al., 2014). 
Activation of angiogenesis is generally therapeutic in ischemic cardiovascular 
disease, peripheral arterial disorder, and also wound healing (Fadini et al., 2010). 
Reducing or hindering angiogenesis could be considered as a treatment for tumors, 
ophthalmic diseases, rheumatoid arthritis, and even some other health conditions 
(Folkman, 1995). Capillary vessels develop and then regress in normal tissues because 
of physiological needs (Moulton, 2001). Any activity can induce angiogenesis in the 
heart as well as skeletal muscle (Chinsomboon et al., 2009). Insufficient physical 
activity results in blood vessels regression (Nybo et al., 2001).  
Figure 1.1: Process of angiogenesis multistep (Bryan et al., 2007) 
 
Capillaries develop in adipocytes as a patient gains weight, and they regress 
upon weight loss (Kern et al., 1995). Obviously, angiogenesis happens through 
lifespan (Giusti et al., 2016). 
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1.3.1 Mechanism of Physiological Angiogenesis 
As an embryo forms, new blood vessels are produced by a procedure known as 
vasculogenesis. Additional modification of vascular network continues throughout 
angiogenesis. That is a complicated multi-step procedure wherein new blood vessels 
are generated out of the available ones. Dysregulation in the process of angiogenesis 
leads to continuous blood vessel formation, which is a critical process in tumor growth 
; thus, angiogenesis can be a suitable target for the treatment of tumors (Thijssen et al., 
2006). Hence, the purpose of using anti-angiogenic factors in cancer therapy aims to 
interrupt critical stages of angiogenesis (Carmeliet, 2000). 
 
1.3.2 Tumor Angiogenesis 
In tumor angiogenesis, cancer cells rely on new blood vessels to nourish them 
once the tumor exceeds 1mm3 in diameter. This occurs when a state of hypoxia exists 
in the central region of the tumor (Zeng et al., 2015). The state of hypoxia inside the 
tumor stimulates the abnormal physiologic conditions affecting the balance between 
pro- and anti-angiogeneic mediators.  If the balance shifts towards pro-angiogenic 
mediators, tumor growth increases.  If the balance moves towards anti-angiogenic 
mediators, tumor growth slows down (Gacche et al., 2014). Tumor angiogenesis 
involves various mediators, but vascular endothelial growth factor (VEGF) and its 
signaling function as the rate-limiting step of this process (Rosen, 2002). Growth and 
modification of new blood vessels not only serves to supply the tumor tissue with 
oxygen and nutrients, but they can also serve as a means for cancer cells to metastasize 
(Figure1.2) (R. K. Jain, 2005). However, the complexity of the interaction between 
tumor and vasculature is profound, and much research remains to be done in this area. 
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Figure1.2: Tumor-neovascularization process (Conti et al., 2013) 
 
Angiogenesis-dependence has been reported in many different types of cancer; 
these respond well to anti-angiogenic therapies. They include cancers of the colon, 
breast, lung, and bladder as well as renal cell carcinoma and non-small-cell lung cancer 
(NSCLC). Additionally, some of these cancers require VEGF for their survival. Anti-
angiogenic therapeutic strategies block or hinder angiogenesis through two major 
mechanisms: blocking the receptor tyrosine kinases intracellularly or neutralizing 
angiogenic factors such as VEGF or its receptors (Ferrara, 2002). 
 
1.3.3 Regulation of Tumor-Angiogenesis 
The growth of a vascular supply is critical not just for development and 
differentiation of organs during embryogenesis; it is also important  for wound healing 
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(Gerwins et al., 2000). Angiogenesis is involved in the pathogenesis of a wide variety 
of diseases: proliferative retinopathies, psoriasis, tumors and rheumatoid arthritis 
(Pandya et al., 2006). Hypoxia is a significant factor of homeostatic systems to regulate 
angiogenesis which connects vascular oxygen source to metabolic requirement 
(Dewhirst et al., 2008). Molecular studies of tumor-angiogenic pathway, highlights the 
importance of hypoxia-inducible factor (HIF) as an important transcriptional controller 
of VEGF molecules. Various tumor-angiogenesis controllers have been identified, 
such as fibroblast growth factor-a (aFGF), bFGF, transforming growth factor-alpha 
(TGF-alpha), TGF-beta, angiogenin, and interleukin-8 (IL-8) (Miyake et al., 2011; 
Weis et al., 2011). Recently it was discovered that vascular endothelial growth factor 
(VEGF) is an endothelial-cell-specific mitogen. VEGF is highly effective with regard 
to vascular endothelial cells and, in contrast to bFGF, contributes to the role the 
molecule performs in the control of tumor angiogenesis. Various other members of the 
VEGF gene family have been identified, such as placenta growth factor (PIGF), 
VEGF-B, VEGF-C and VEGF-D. There is strong evidence demonstrating that VEGF 
acts as a critical factor in growth of tumor and metastasis (Saharinen et al., 2011). 
 
1.3.4 VEGFs and VEGF Receptors 
VEGF, first known as vascular permeability factor (VPF), was discovered by 
Senger et al., as a part of tumor-secreted factors and inducing leakage of skin blood 
vessels (Weis et al., 2005). Later in 1989, Ferrara et al. isolated VPF, which was then 
renamed as VEGF (Ribatti, 2007). VEGFs are a family of secreted dimeric 
glycoproteins that include VEGF-A (commonly referred to as VEGF), VEGF-B, 
VEGF-C, VEGF-D in mammals, and VEGF-E and VEGF-F found in other species 
such as viruses and snake venom, respectively (Ylä-Herttuala et al., 2007). The VEGF 
8 
family also includes PlGF- 1 and 2 (Ferrara, 2010). The effects of these factors are 
mediated through binding to their receptors (VEGFR-1, VEGFR-2  and VEGFR-3 
(Partanen et al., 2000). VEGFR-1 and -2 interacts with neuropilin-1 while VEGFR-3 
only associates with neuropilin-2 (Suarez et al., 2006). 
Diversity on the effects of VEGF receptors arises from receptor dimerization 
potentials (Robinson et al., 2001). Dimerization between VEGFRs 1 and 2 as well as 
VEGFRs 2 and 3 have been shown to mediate some of the physiological effects of 
VEGF superfamily members (Holmes et al., 2007). Furthermore, VEGFRs isoforms 
each lead to discrete effects compared to their counterparts in ECs (Bottos et al., 2009): 
VEGFR-1 activation leads to a ‘decoy effect’ as a VEGF sequestrate or VEGF-trap 
(Al‐Husein et al., 2012); while VEGFR-2 binding to its ligand leads to proliferation, 
migration, survival, and angiogenesis (Cross et al., 2003). Similar to VEGFR-2, 
VEGFR-3 mediates these cellular processes but primarily in lymphatic blood vessels 
(Cross et al., 2003). 
 
1.4  Treatment of Melanoma 
 Melanoma is a highly angiogenic dependent type of cancer. Treatment for 
melanoma is limited are in spite of improvements in immunotherapy as well as targeted 
therapy (Olszanski, 2014). For patients with surgically resected, dense (2 mm) initial 
melanoma with or even without localized lymph node metastases, the most common 
adjuvant treatment is interferon (IFN). However, the benefits of IFN are debatable, as 
tumors may recur and survival rates are not certain. For single-drug treatment in 
patients with stage IV metastasis, the American Joint Committee on Cancer (AJCC) 
recommends dacarbazine (Fischkoff et al., 2005). However the treatment success rate  
for dacarbazine and its oral analogue, temozolomide (Middleton et al., 2000), is only 
15%, and even this is usually temporary. Amongst other treatment alternatives, 
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immunotherapy by using high-dose interleukin (IL)-2 obtains long-term, long-lasting, 
complete results in a small ratio of patients. However, the drug remains unproven in 
an official phase III, randomized proportional study on humans (Agarwala et al., 
2002). Bio chemotherapy thus has some positive effect, but has not been shown to 
significantly enhance survival rates due to its high toxicity, as opposed to 
chemotherapy alone (Ives et al., 2007). Obviously, new treatment options are required. 
In recent years, enhanced drug delivery technologies have been researched, to 
overcome the limitations of the traditional techniques. Drug delivery for cancer 
chemotherapy is a significant factor in the development of new techniques. 
Lipoproteins as drug delivery systems are a desirable field of investigation (Sharman 
et al., 2004). Lipophilicity as well as molecular size is the most crucial criteria in 
enabling drug molecules to cross the normal membrane so they can be consumed 
efficiently after administration. For better bioavailability, herbal products need to have 
proper balance between hydrophilicity (to dissolve into the gastro-intestinal liquids) 
and lipophilicity (to pass lipidic bio-membranes). Numerous phytoconstituents 
including glycosilated polyphenolics, flavonoids, glycosides, tannins, in spite of 
remarkable water solubility and bioactivity in vitro, reveal significantly less in vivo 
activity because of their weak lipid solubility or inappropriate molecular size, causing 
inadequate absorption and poor bioavailability (Manach et al., 1996). Standardized 
herbal extracts containing polar phytoconstituents such as flavonoids, terpenoids, 
tannins, xanthones utilize novel drug delivery systems, demonstrating greater 
absorption as they cross the biological membrane, which results in improved 
bioavailability (Cornwell et al., 1993). Moreover more active compounds will reach 
their targeted destination in the body at an effective dosage, than is the case with 
traditional herbal extracts or phytomolecules (Borm et al., 2004). Therefore, the 
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medicinal effect is better, more recognizable and longer-lasting (Vintiloiu et al., 2008). 
So improving novel drug delivery systems may result in improved treatment of cancer 
patients using herbal active compounds and extracts.  
Melanoma is the sixth most common cancer in the U.S., with approximately 44,200 
latest patients declared in 1999 (Parkin et al., 1999). This figure has increased hugely 
since then, with over 1.4 million cases in 2015 (Ferlay et al., 2015). The subcutaneous 
type (B16) is commonly used for the investigation of treatment in several other tumor 
types (Marty et al., 2006).  
  The most crucial part of cancer metastasis is the distribution of melanomas to 
the lymphatic vessels that surround the mass of the tumor tissue (Dadras et al., 2003).  
At the same time, or shortly afterwards, melanoma cells may metastasize to invade the 
lungs, the liver, brain tissue, and other sites (Steeg, 2006). Exposure to ultraviolet 
radiation is known to cause genetic changes in skin, which modulate the cutaneous 
immune response and increase production of several growth factors (Matsumura et al., 
2004). This causes uncontrolled proliferation of melanocytes, which, in turn, 
dramatically increases the consumption of oxygen and nutrients, eventually leading to 
cell starvation and hypoxia (Haass et al., 2005). To fulfill this increasing demand, 
additional vasculature needs to be developed. Thus, to increase the blood supply, the 
tissue begins to produce a spectrum of growth factors that trigger the process of 
angiogenesis (Claffey et al., 1996). Studies using human melanoma xenograft models 
in nude mice indicated that melanoma tumor cells serve as a source of several growth 
factors, including but not limited to vascular endothelial growth factor (VEGF) and 
basic fibroblast growth factor (bFGF).  Both of these growth factors have a powerful 
stimulation effect on angiogenesis (Claffey et al., 1996). Science has made 
considerable advances in recent years towards understanding the molecular 
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mechanisms of tumor growth.  Modern technology makes it possible to detect and treat 
various human cancers in ways never imagined before, but our knowledge about the 
mechanisms behind cutaneous tumor angiogenesis and metastasis is still in its infancy 
(Mahabeleshwar et al., 2007). 
Angiogenesis in melanoma is stimulated by a variety of growth factors. Among 
these are VEGF, bFGF, acidic FGF, platelet-derived growth factor (PDGF), and 
transforming growth factors  and (TGF- and ) (Ferrara, 2002). Angiogenesis serves as 
a key point in melanoma tumor growth and metastasis (Mahabeleshwar et al., 2007). 
 
1.4.1 Chemotherapy 
Chemotherapy is commonly used to treat advanced stage of melanoma and it is 
also often used in palliative treatment options for stage IV metastatic cancer (Mac 
Manus et al., 2001); dacarbazine is the most frequently used principal 
chemotherapeutic drug for metastatic melanoma therapy (Middleton et al., 2000). Both 
of conventional chemotherapies and radiotherapy are generally inefficient in 
metastatic melanoma patients (Engell-Noerregaard et al., 2009). 
 
1.4.2 Biochemotherapy 
Biochemotherapy (e.g., cisplatin, vinblastine, and dacarbazine combined with 
IFN- IL-2) increases response rates but has not been shown to significantly improve 
survival compared to chemotherapy alone in randomized phase II and III trials (S. 
Bhatia et al., 2009).  
Despite decades of clinical research, patients with advanced melanoma continue 
to have a poor prognosis, and no agents have shown statistically significant 
improvement in overall survival in a phase III trial in patients with metastatic 
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melanoma (Atkins et al., 2008). For high-risk, resected disease, adjuvant therapy with 
IFN- has been shown to consistently increase relapse-free survival, as well as overall 
survival in some studies (Cameron et al., 2001). Serum levels of angiogenin, VEGF, 
bFGF, and IL-8 were significantly increased in melanoma patients compared to 
healthy controls (Ugurel et al., 2001). 
The effective management of malignant melanoma therapy has remained 
centered around the surgeon. The arrival of anti-angiogenic agents as the ‘fourth’ 
cancer treatment joining the ranks of surgery, chemotherapy and radiotherapy has been 
a source of renewed hope. 
 
1.4.3 Medicines Discovered To Treat Melanoma  
Metastatic melanoma is very impervious to chemotherapy, radiation treatment, 
hormonal treatment and current immunotherapeutic methodologies (Miller et al., 
2016). All known therapeutic methods revealed no noteworthy effect on survival with 
new medications. Angiogenesis is a legitimate focus in melanoma therapeutics. 
Hindrance of angiogenesis through the focusing of vascular endothelial development 
factor (VEGF) has long been utilized as a part of the treatment of tumors, although its 
antitumor action remains ineffective (A. Sharma et al., 2005). 
 
1.4.4 Anti-angiogenesis Therapy  
Angiogenesis is characterized as the development of new blood vessels from a 
previous vasculature and is as prerequisite for tumor survival and movement past a 
couple of hundred microns in diameter (Fukumura et al., 2008). Altogether for a cell 
to survive it must be guaranteed to have a steady supply of both oxygen and 
supplements and thus it cannot be more than a couple of hundred micrometers from 
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the closest vein (Lesart et al., 2012). For a tumor to multiply the size, it must create 
satisfactory levels of pro-angiogenic development components to initiate 
neighborhood angiogenesis (Bergers et al., 2003). It is this development which 
characterizes angiogenesis as one of the signs of malignancy (Carmeliet, 2003). 
Malignant melanoma has been reported as an angiogenic tumor type, 
unmistakably showing new vessel arrangement as an essential advance in infection 
movement from atypical melanocytes, through outspread development to the forceful 
vertical development stage (Garcia-Barros et al., 2003).  
Vascular Endothelial Growth Factor (VEGF) exists in mammals as a few related 
groups of glycoproteins including VEGF-A, B, C, D, and E, which intervene through 
enactment of the class III tyrosine kinase receptors VEGFR-1, VEGFR-2, and 
VEGFR-3 (Hiratsuka et al., 2002). VEGF-A, which is regularly alluded to as VEGF, 
is thought to be a standout amongst angiogenesis factors, and is overexpressed in all 
known cancerous tumors (Martin et al., 2012). VEGF attaches to  VEGFR-2 to initiate 
the angiogenic reaction, with actuation bringing about endothelial cell expansion and 
movement, alongside lumen development and expanded vessel dilatation and 
porousness (Lyden et al., 2001). 
There were great expectations in early research that angiogenic treatments would 
transform oncology practice, but in point of fact advances in the treatment of 
melanoma have been limited.  Some few patients had no reaction, while others showed 
a slight response immediately follow treatment.  There are many possible factors which 
may have influenced these results, and it is conceivable that every patient will respond 
in a unique way, requiring tailored interventions to bypass these complications (R. K. 
Jain et al., 2009). 
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Dacarbazine is an alkylating agent affirmed by the United States Food and Drug 
Administration (FDA) for the treatment of melanoma. Dacarbazine is considered a 
standout amongst the best chemotherapy operators for metastatic melanoma (Pitts et 
al., 2000).  
Temozolomide is an alkylating operator identified with dacarbazine, which has 
superb oral bioavailability.  It was recently approved through Phase III human trials 
(Herrlinger et al., 2017).  
IL-2 is a lymphokine that fortifies T-cell multiplication and capacity. It was 
affirmed by the FDA in 1998 for the treatment of metastatic melanoma. High 
measurement IL-2 appears to profit a few patients with metastatic melanoma, with 
finish and fractional reactions rates of 6% and 10%, individually (Chong, 2008).  
Bevacizumab, Axitinib, Lenvatinib (E7080) and Etaracizumab (MEDI-522) are 
a portion of the medications in antiangiogenic treatment against melanoma. 
Nonetheless, more examinations are expected to assess the utilization of them in 
melanoma (Velho, 2012). 
 
1.5 Potential Targets and Respective Anti-Angiogenic Agents 
According to the mechanism of action, anti-angiogenic agents are classified 
into ″(1) endothelial growth factors inhibitors, (2) EC signal transduction inhibitors, 
(3) inhibitors of EC proliferation, (4) inhibitors of matrix MMPs, (5) inhibitors of EC 
survival, and (6) inhibitors of endothelial bone marrow precursor cells″ (Gasparini et 
al., 2005). Depending on their targets, they are typically categorized as direct, indirect 
or mixed agents with anti-angiogenic effects.  Further, the agents are defined as 
exclusive if they were deliberately designed to block angiogenesis as the sole 
mechanism of action; an example of such an agent is bevacizumab. Those that were 
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introduced as anticancer agents that were later found to target angiogenesis are known 
as inclusive agents (for example, bortezomib) (Chau et al., 2008). 
The NCI (National Cancer Institute) included a mechanistic classification of 
angiogenesis inhibitors (Efferth, 2005). They are classified into (1) agents that directly 
inhibit endothelial cells (integrin antagonists are included) (2) or those capable of 
interfering with signaling cascades and finally (3) agents that inhibit the ability of 
endothelial cells to breakdown extra-cellular matrix (ECM) (M. K. Gupta et al., 2003). 
Some of the inhibitors modify the classification to include a ″miscellaneous″ group 
and put integrin inhibitors in a different category (Al‐Husein et al., 2012). 
 
1.6 Anti-Angiogenic Agents In Cancer Therapy 
Three major classes of agents which target VEGF have been developed: 
monoclonal antibodies, VEGF decoy receptor, and small molecule tyrosine kinase 
inhibitors (TKIs) (Ferrara et al., 2003). These agents are currently in clinical practice 
or investigation as a monotherapy or in combination with cytotoxic chemotherapy or 
radiation (R. K. Jain et al., 2006). 
 
1.7 Mechanism of Anti-Angiogenic Therapy 
Anti-angiogenic therapy can lead to reduced vessel permeability and blood 
perfusion, and vascular shrinkage which decreases the possibility of a tumor receiving 
oxygen and nutrients (Wedam et al., 2006). Theoretically, anti-angiogenic therapy 
may return tumor blood vessels to their normal state, and improve the quality and 
delivery of cytotoxic therapeutic agents (R. K. Jain et al., 2007). Hence, anti-
angiogenic agents function by reducing the permeability of blood vessels in tumors, 
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and the dispersion of interstitial fluids. This leads to a decline in interstitial pressure, 
and, eventually, reduces tumor hypoxia (Maeda et al., 2009).  
If anti-angiogenic therapy is used along with cytotoxic agents, the effect of these 
agents increases, while tumor vessels are simultaneously normalized (Damge et al., 
1990). 
A number of anti-angiogenic therapeutic agents are undergoing clinical trials. 
These agents can be classified into three categories: The first comprises the endothelial 
cell growth inhibitors, the preeminent of which is endostatin. This class of 
angiogenesis inhibitors induces apoptosis and inhibits endothelial cell growth (Decker, 
1998). The second category includes drugs, which act as angiogenesis-signaling 
blockers, an example of which is Avastin®. They are inhibitors of the basic fibroblast 
growth factor (bFGF) and VEGF (Folkman, 2002). The third category is composed of 
the receptor blockers which inhibit ECM destruction, like the inhibitors of MMPs, 
which act by inhibiting the receptor activities of multiple growth factors (Guba et al., 
2002). 
 
1.8 Traditional Therapeutic Plants for the Treatment of Cancer  
Some kinds of plants obtain special effects in cancer treatment and control since 
long time ago. Previous reports of studying anticancer effect in such plants expressed 
numerous natural constituents that reveal anticancer effects. The significant toxic side 
effects of chemotherapeutic medicines frequently causes intolerable difficulties to 
patients that prevents them to continue treatment. Numerous therapeutic methods come 
up with cancer treatment using herbal products. Currently, there are four categories of 
anticancer products in market, which derived from herbal resources. These therapeutic 
constituents include vinca alkaloids, taxanes, epipodophyllotoxins as well as 
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camptothecin (Pan et al., 2010). However, so many plants have potential to be used as 
anticancer or chemo-protective product because of containing specific active 
ingredients in different percentages. Several researches have concentrated on 
particular characteristics of herbs that can protect the patients from chemotherapy side 
effects. Abrus precatorius is one of the plants that its chemo-protective effects was 
studied in Yoshida sarcoma model of rats (M. Bhatia et al., 2013; Gul et al., 2013). 
Furthermore, in other study, the anti- sarcoma effects of Albizzia lebbeck in mice 
model was investigated (R. Jain et al., 2010).  
Anticancer plants contain numerous compounds with antioxidants, 
antiangiogenic and anti-inflammation effects. These therapeutic properties causes their 
cancer suppression effects. Transdermal ingenol mebutate, derived from Euphorbia, 
was approved in 2012 by the U.S. Food and Drug Administration (FDA) for treatment 
of pre-cancer lesions (Francis et al., 2013). Even though, the possible toxicity effects 
and safety of most of these herbal products have not been evaluated in long term 
clinical trial studies, they are available without any proper regulation in some countries 
which needs to be controlled (Ekor, 2014). 
Paclitaxel is an alkaloid extracted from Taxus brevifolia that has shown 
anticancer effect. It was investigated that paclitaxel blocks proliferation and suppress 
tumor growth. However, in further studies its toxic effects evaluated to be significant. 
In order to avoid its side effects another group designed and evaluated dermal 
paclitaxel-ethosomal formulation to treat skin cancer (Paolino et al., 2012).   
One of the active compounds in Silybum marianum is silymarin. Some of the 
pharmacological effect of this compound is anti-oxidant as well as anti-inflimmatory 
effects. Silymarin has reported as anticancer compound specifically in breast and 
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prostate cancer. In other studies dermal formulation of silymarin demonstrated 
anticancer results in different stages of skin cancer (F'guyer et al., 2003).  
Orthosiphon stamineus is one of therapeutic herbs that has demonstrated promising 
anticancer and antiangiogenic impacts in different angiogenic-dependent tumors like 
colon and breast cancer (Dolečková et al., 2012; Sahib et al., 2009).  
 
1.8.1 Orthosiphon stamineus   
O. stamineus  or Misai Kucing (the local name for O.S) is a Malaysian 
therapeutic plant which grows well in numerous nations especially in Southeast Asia 
(L. Price et al., 2008). Several studies have demonstrated the pharmacological 
possibilities of this plant, since O. stamineus is used traditionally for treating maladies 
including urinary, cardiovascular, and liver and digestive problems.  
 
1.8.1(a) Traditional Uses of O. stamineus  
Orthosiphon stamineus Benth. (Lambiaceae) is an imperative restorative herb. 
Different in vitro and in vivo models have been used to utilize the bioactive 
phytochemicals, including the flavonoids, terpenoids and basic oils, in this herb 
(Ramesh et al., 2014). Early traditional practitioners utilized the leaves of O. stamineus  
(O.S) as a diuretic, and fused them into arrangements intended to assist the evacuation 
of kidney stones (Y.-S. Zhong et al., 2012). They were also used for a remarkable 
range of other ailments, ranging from diabetes mellitus to tonsillitis, and even such 
things as epilepsy, syphilis, gout and psoriasis (Akowuah et al., 2005). O. stamineus 
has pharmacological properties which can be helpful in various pathophysiological 
conditions. Many studies on the phytochemical and pharmacological effects of 
O.stamineus  have been conducted (Abdullah et al., 2009). 
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1.8.1(b) Pharmacological Properties of O. Stamineus  
The pharmacological impacts of O.S are due to the presence of polyphenols, 
glycosides, lipophilic flavones, triterpenes, and diterpenes in its concentrates, showing 
various bioactive compounds, for example, rosmarinic corrosive (RA), sinensetin 
(SIN), eupatorin (EUP), betulinic acid, olenolic acid, 3′-hydroxy-5, 6, 7, 4′-
tetramethoxyflavone (TMF) and a few caffeic acid subordinates  (Ho et al., 2010) .  
A phytochemical analysis of O.S has shown that it includes monoterpenes, 
diterpenes, triterpenes, saponins, flavonoids, basic oils and a few long-chain natural 
acids, which still should be investigated and recognized (Sosa et al., 2005). 
Pharmacological analysis of various O.S extracts show that the plant has a range of 
useful effects.  These include cell reinforcement, antimicrobial and antitumor 
properties, nephroprotective benefits, and as an inhibitor of angiogenesis (Akowuah et 
al., 2005). 
Eupatorin displayed cell development restraint and apoptosis enlistment 
especially in tumor cells in spite of being a nonspecific inhibitor of a few protein 
kinases (A. Gupta et al., 2014). It has been demonstrated that eutaporin is cytotoxic, 
and can inhibit the process of angiogenesis, possibly through restraint of VEGFRs 
(Dolečková et al., 2012).  
Certain concentrations of O.S suppressed the key angiogenic factor of VEGF 
both in vitro and in vivo (Foaud Saleih R Al-Suede et al., 2014). This could be 
attributed chiefly to the polyphenolic substances, which are rich in cancer-prevention 
properties.  These agents include: eutaporin, caffeic acid subsidiaries, sinensetin, 3'- 
hydroxy-5,6,7,4'- tetramethoxyflavone, polymethoxylated flavonoids and terpenes 
(Pang et al., 2014). Flavonoids and phenolics have extremely encouraging 
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antiangiogenic properties (Lai et al., 2004). Other non-flavonoid polyphenols, for 
example, rosmarinic acid and betulinic acid also add to the anti-angiogenic impact of 
polyphenol-rich plants (Ahamed et al., 2012). In extensive preclinical models, the 
angiogenic procedure appears to have induced a significant delay in the development 
of tumors through the hindrance of VEGF; there are also clinical advantages to this 
approach (H. X. Chen et al., 2009). Diterpenes confined from O. stamineus appear to 
exhibit antiproliferative effects against liver metastatic murine colon 26-L5 carcinoma 
cells (Awale et al., 2001). Additionally diterpenes reduced the tumor-promoter-incited 
irritation of 12-O-tetradecanoylphorbol-13-acetic acid derivation in mice (Schmidt et 
al., 1989). Moreover, it fundamentally repressed key steps of angiogenesis in 
endothelial cells, for example, movement and tube arrangement (Ullah et al., 2008). 
 
1.8.1(C) Orthosiphon Stamineus Is Rich in Anticancer Phytoconstituents 
Rosmarinic acid (RA) is a dynamic caffeoyl ester found in O. stamineus. It 
inhibits several critical steps of angiogenesis including proliferation, migration and 
tube arrangement of endothelial cells. It also reduced retinal neovascularization in a 
mouse model of retinopathy (Y. Sharma et al., 2017). RA restrained neutrophil elastase 
discharge and reduced thrombin movement (Porath, 2005). RA is considered a solid 
cancer prevention agent, mitigating antimicrobial effects, and the cell reinforcement 
action of rosmarinic acid is more grounded than that of vitamin E (Alayoubi et al., 
2015; K. S. Rao et al., 1968). RA is the dynamic standard of numerous compounds in 
Lamiaceae family, with antioxidant properties (Gülçin et al., 2007). Rosmarinic acid 
has shown a powerful anticancer, lipid peroxidative and apoptotic impact in DMBA-
incited skin carcinogenesis (Hur et al., 2004; Sharmila et al., 2012). Comparative tests 
demonstrated the anticancer effect of Perilla frutescens, a plant in which RA is an 
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active ingredient, by means of two free systems: hindering the tumor’s reaction to the 
drug, and reducing the activity of oxygen radicals (Banno et al., 2004). Another 
investigation on human tumor cell line demonstrated that RA might have an effect 
against COX-2 initiation by AP-1-inciting operators in both disease and nonmalignant 
mammary epithelial cells (Scheckel et al., 2008).  
Methoxylated flavonoids (eupatorin and sinensetin) are in a critical class of 
bioactive compounds discovered richly in O. stamineus  (Akowuah et al., 2004). 
Eupatorin inhibits in vitro proliferaton of cancer cells (Androutsopoulos et al., 2008). 
Research has demonstrated the capacity of eupatorin to nonspecifically repress 
numerous protein kinases (Sak et al., 2015), which makes it a promising operator in 
anticancer research (Androutsopoulos et al., 2008). Another comparable investigation 
announced that eupatorin strongly initiates apoptosis in different malignancy cell lines 
and smothers disease cell multiplication in organotypic 3D cell culture 
(Androutsopoulos et al., 2008). 
Tetramethoxyflavone has been shown to cause the activation of protein PKCε. 
Down-regulation of the instigated PKCε level by zapotin (a flavonoid) is associated 
with enhanced apoptosis (Toton et al., 2012). Another study of tumor cell lines 
demonstrated that tetramethoxyflavone showed the cytotoxic property by enhancing 
the mitochondrial membrane potential in K562 and K562/adr in human blood growth 
cells (Khajapeer et al., 2016). Comparable studies exhibited that tetramethoxyflavone 
has a high inhibitory impact on the multiplication of human nasopharygeal carcinoma 
(CNE) cells and initiates the apoptosis of CNE cells by decreasing the mitochondrial 
membrane potential and enhancing the outflow of Caspase3 and Caspase9 (Cao et al., 
2014). Another comparable study discovered that tetramethoxyflavone causes cell 
demise through an apoptotic pathway (Sergeev et al., 2006).   
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Sinensetin prompts apoptosis and CYP1-interceded antiproliferation in human 
tumors cells (Ahamed et al., 2012). An investigation revealed that sinensetin is 
expected as a novel and powerful second-age flavonoid chemo-sensitizer, since 
sinensetin has high therapeutic properties of being a non-transportable tumor inhibitor 
(Choi et al., 2004). 
 
1.8.2 Challenges in Topical Drug Delivery Systems 
Skin is an organ consists of multiple layers with three different histological 
tissues. Epidermis is the outer layer of skin, which makes the skin tone and acts like a 
waterproof layer (Chisholm et al., 2012). The second layer is the dermis, which 
consists of dense connective cells, follicles of hair, and sweat glands. Further 
subcutaneous tissue mass is called the hypodermis, consisting of fat and connective 
tissues (Khavkin et al., 2011). Human skin is an effective, selective barrier to chemical 
permeation, although the skin as a route for delivery can offer many advantages, 
including avoidance of first-pass metabolism, lower fluctuations in plasma drug levels, 
targeting of the active ingredient for a local effect, and good patient compliance 
(Amnuaikit et al., 2005). 
Generally, the epidermis (especially the stratum corneum) controls most small, 
hydrophilic, and non-electrolytic diffusion of drugs through systemic blood 
circulation. So, to enhance the flux of the drug, the barrier interference is reduced. 
Several techniques have been utilized recently to conquer skin barrier characteristics 
(Alexander et al., 2012).  
A large portion of the bioactive constituents of phytomedicines are flavonoids 
(e.g., anthocyanidins from bilberry, catechins from green tea, silymarin). Numerous 
flavonoids are ineffectively ingested; the poor assimilation of flavonoid supplements 
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is likely because of two components. First is having various ring particles that make 
them too substantial to be in any way consumed by straightforward dispersion. 
Furthermore, flavonoid atoms commonly have poor miscibility with oils and different 
lipids, which restricted their capacity to pass through the skin (Montenegro et al., 
2007). 
The main issue that needs to be considered in dermal and transdermal delivery 
of herbal products is their solubility whether in water or lipid. The phytoconstituents 
which are water soluble have less chance to permeate to stratum corneum (SC) 
becasuse it is composed of insoluble bundled keratins surrounded by a cell envelope, 
stabilized by cross-linked proteins and covalently bound lipids (Satyam et al., 2015). 
For example polyphenol compounds due to their hydrophilicity are not thoroughly able 
to penetrate to SC, so it shows weaker efficacy compared to its oral administration 
(Saraf, 2010). Several approaches have been developed to weaken this skin barrier 
(Rothbard et al., 2000), allowing for increasing the bioavailability of topical drugs and 
many cosmetic chemicals is the use of vesicular systems, such as liposomes (Elsayed 
et al., 2006). Even though lipid soluble botanical active compounds can penetrate 
through SC but some particular enhancers ease this transfer by coating in some vesicles 
(Chanchal et al., 2008).  
Liposomal topical drugs even though improved the percentage of drug 
penetration through SC but this enhancement was not too much because morphological 
stability of such vesicles were rational(Liang et al., 2015). In a comparison study 
between different types of topical vesicles results revealed that liposome can entrap 
less active compound which has potential to have leakage. It showed conventional 
liposomal vesicles can be considered as big size of vesicle that can consequently cause 
the lower bioavailability (Bragagni et al., 2012). 
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Some research groups worked on designing similar vesicles to conventional 
liposomes but with elastic morphology properties with high penetration rate and no 
leakage to enhance the bioavailability of topical botanical drugs as much as possible 
(Ascenso et al., 2015). So ethosome as flexible vesicle was introduced which could 
increase the stability of most of drugs with different molecular weight for dermal and 
transdermal application purpose (Jaiswal et al., 2016). 
 
1.8.3 Definition of Ethosome Complex 
Ethosome was created by Touitou et al. in 1997 as extra novel lipid vesicles 
made out of ethanol, phospholipids, and water (Elsayed et al., 2006). This kind of 
vesicle has the potential to enhance the skin conveyance of different medications 
(Godin et al., 2004). Ethanol is a proficient permeation enhancer that acts by 
influencing the intercellular part of the SC. 
Ethosomal transporters are flexible vesicles that are composed of 
hydroalcoholic or hydro/glycolic phospholipids, ethanol (moderately high 
concentration), and water (Elsayed et al., 2006). The high concentration of ethanol 
increases porousness of the SC to provide an entrance for the medication upon topical 
application. This ethosomal system may be used to deliver different types of drugs, 
such as acyclovir, salbutamol, Insulin, cyclosporine, fluconazole, minodixil, and more 
(Mahale, 2011). Methods for preparation of the vesicles can utilize cold, heat, or 
rehydration methods (Pratima et al., 2012). The size of ethosomal vesicles can be 
controlled, to some extent, using sonication (Satyam et al., 2015).  
 
1.9 Ethosome Technology 
The primary problem of topical medications is poor penetration of compounds 
into the human skin (Moser et al., 2001). .Ethosomes are phospholipid-based versatile 
